gip plus glp 1 GLP-1 and in Type Diabetes Therapy: A Time for Reappraisal? GLP-1 + GIP Injections -

Furthermore, survodutide at doses of 1.8 mg or higher resulted in more substantial weight loss than semaglutide 1.0 mg after the same treatment period

DrugBank 6.0: The DrugBank Knowledgebase for 2024

N.CarlessiR.BittencourtP

Martini, N.A

A meta-analysis of 76 RCTs has recently found that compared with placebo or active controls, GLP-1RA treatment was associated with an increased risk of gallbladder or biliary diseases (RR, 1.37

Patients may need a more careful discussion if they have a history of: Previous NAION in one eye Significant optic nerve crowding Diabetes with vascular complications Sleep apnea, especially untreated sleep apnea High blood pressure or low nighttime blood pressure Cardiovascular disease Sudden unexplained vision loss in the past This does not automatically mean a GLP-1 medication is unsafe, but it does mean the patient should have a personalized risk-benefit discussion with their medical provider